Search
-
Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?
GLP-1s are more than just weight loss drugs. They're a chance to rewrite our evolutionary story, to take control of our biology in a way never before possible.
-
The Heart Truth: Understanding What We Don’t Know About Cardiac Health
New Ipsos survey conducted across six countries reveals that despite 84% claiming to be sufficiently informed on the cardiac health, only less than a half are.
-
How Trump reshapes the world for brands
Nine global trends explain the ways the new administration will affect the way you do business
-
U.S. Biosimilars: Greater Access and New Commercial Models
Read more about the primary considerations that manufacturers – of both biosimilars and originator products – must factor into strategic plans going forward.
-
What the Future: Food
Revisit our on-demand webinar for exclusive polling data on nutrition, sustainability, diets and consumer spending, plus highlights and excerpts from interviews with industry experts.
-
How brands can appeal to Gen Z’s desire to ‘live for today’
Why focusing on future benefits, like with sustainable products, may not be the most compelling angle for brands trying to connect with younger consumers
-
How GLP-1s create opportunities for brands and retailers to address new self-care needs
CPG companies and retailers can act as trusted advisors and provide valuable advice and information, such as diet plans, exercise regimens, and ways to manage medication side effects. Here’s where to start.
-
Golden Years, Golden Opportunities
Read more about what an aging consumer base means for businesses, how to tap into the wealth held by this cohort, and who among older adults is spending – and on what.
-
Ipsos Update - November 2024
Mental Health, AI, Infrastructure … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.